CN1043610C - 新的治疗剂 - Google Patents

新的治疗剂 Download PDF

Info

Publication number: CN1043610C
Authority: CN; China
Prior art keywords: chemical compound; treatment; purposes; administration; cyclopropyl methyl
Prior art date: 1992-07-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CN93116874A

Other languages

English (en)

Chinese (zh)

Other versions

CN1114880A (zh

Inventor

B·A·施派泽

K·G·艾利斯

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SmithKline Beecham Ltd

Original Assignee

SmithKline Beecham Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-23

Filing date

1993-07-22

Publication date

1999-06-16

1993-07-22 Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd

1996-01-17 Publication of CN1114880A publication Critical patent/CN1114880A/zh

1999-06-16 Application granted granted Critical

1999-06-16 Publication of CN1043610C publication Critical patent/CN1043610C/zh

2013-07-22 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims abstract description 23
229940125904 compound 1 Drugs 0.000 claims abstract description 18
208000008589 Obesity Diseases 0.000 claims abstract description 10
235000020824 obesity Nutrition 0.000 claims abstract description 10
150000001875 compounds Chemical class 0.000 claims description 28
MWAMGTOITZRWMI-UHFFFAOYSA-N 8-amino-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(N)N2 MWAMGTOITZRWMI-UHFFFAOYSA-N 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 2
229940126701 oral medication Drugs 0.000 claims 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
238000000034 method Methods 0.000 abstract description 22
241000124008 Mammalia Species 0.000 abstract description 6
231100000252 nontoxic Toxicity 0.000 abstract description 2
230000003000 nontoxic effect Effects 0.000 abstract description 2
238000011321 prophylaxis Methods 0.000 abstract 2
230000000069 prophylactic effect Effects 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
229940075420 xanthine Drugs 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 description 13
239000000203 mixture Substances 0.000 description 12
235000012631 food intake Nutrition 0.000 description 10
230000037406 food intake Effects 0.000 description 9
230000037396 body weight Effects 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
235000013305 food Nutrition 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000004087 circulation Effects 0.000 description 3
230000003203 everyday effect Effects 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000005286 illumination Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000001954 sterilising effect Effects 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000031648 Body Weight Changes Diseases 0.000 description 1
101100149252 Caenorhabditis elegans sem-5 gene Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010022489 Insulin Resistance Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004579 body weight change Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000009266 disease activity Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000013265 extended release Methods 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
238000003304 gavage Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003292 glue Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000004519 grease Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
238000000465 moulding Methods 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
-1 oleic acid sorbitan ester Chemical class 0.000 description 1
229940100691 oral capsule Drugs 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
229940096978 oral tablet Drugs 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000012797 qualification Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CN93116874A 1992-07-23 1993-07-22 新的治疗剂 Expired - Lifetime CN1043610C (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9215633.0		1992-07-23
GB929215633A GB9215633D0 (en)	1992-07-23	1992-07-23	Novel treatment

Publications (2)

Publication Number	Publication Date
CN1114880A CN1114880A (zh)	1996-01-17
CN1043610C true CN1043610C (zh)	1999-06-16

Family

ID=10719151

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN93116874A Expired - Lifetime CN1043610C (zh)	1992-07-23	1993-07-22	新的治疗剂

Country Status (9)

Country	Link
EP (1)	EP0651642A1 (th)
JP (1)	JPH07509456A (th)
CN (1)	CN1043610C (th)
AU (1)	AU4714393A (th)
GB (1)	GB9215633D0 (th)
MX (1)	MX9304435A (th)
TW (1)	TW258663B (th)
WO (1)	WO1994002150A1 (th)
ZA (1)	ZA935339B (th)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5783408A (en) *	1995-06-07	1998-07-21	Hamilton; Bradford S.	Method for screening potential anti-obesity agents
KR100926247B1 (ko) *	2001-02-24	2009-11-12	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
US6869947B2 (en)	2001-07-03	2005-03-22	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2003004496A1 (en) *	2001-07-03	2003-01-16	Novo Nordisk A/S	Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
EP1463727A2 (en) *	2001-09-19	2004-10-06	Novo Nordisk A/S	Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) *	2002-11-21	2004-06-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
WO2005023253A1 (en)	2003-09-05	2005-03-17	Altana Pharma Ag	Use of pde4 inhibitors for the treatment of diabetes mellitus
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de)	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2006222060B2 (en)	2005-03-08	2011-09-01	Takeda Gmbh	Roflumilast for the treatment of diabetes mellitus
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR101452915B1 (ko)	2006-05-04	2014-10-21	베링거 인겔하임 인터내셔날 게엠베하	다형태
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2736421A1 (en)	2008-09-10	2010-03-18	Boehringer Ingelheim International Gmbh	Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja)	2008-12-23	2012-06-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	有機化合物の塩の形態
TW201036975A (en)	2009-01-07	2010-10-16	Boehringer Ingelheim Int	Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en)	2010-05-05	2023-01-03	Boehringer Ingelheim International Gmbh	A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko)	2010-06-24	2013-08-21	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en)	2011-07-15	2019-04-23	Boehringer Ingelheim Int	SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013171167A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Medical use of a dpp-4 inhibitor
EP4233840A3 (en)	2016-06-10	2023-10-18	Boehringer Ingelheim International GmbH	Combinations of linagliptin and metformin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0389282A2 (en) *	1989-03-23	1990-09-26	BEECHAM - WUELFING GmbH & Co. KG	Xanthinederivatives, process for their preparation and their pharmaceutical use

1992
- 1992-07-23 GB GB929215633A patent/GB9215633D0/en active Pending
1993
- 1993-07-21 JP JP6504294A patent/JPH07509456A/ja active Pending
- 1993-07-21 EP EP93917883A patent/EP0651642A1/en not_active Withdrawn
- 1993-07-21 WO PCT/GB1993/001539 patent/WO1994002150A1/en not_active Ceased
- 1993-07-21 AU AU47143/93A patent/AU4714393A/en not_active Abandoned
- 1993-07-22 MX MX9304435A patent/MX9304435A/es unknown
- 1993-07-22 CN CN93116874A patent/CN1043610C/zh not_active Expired - Lifetime
- 1993-07-23 ZA ZA935339A patent/ZA935339B/xx unknown
- 1993-07-27 TW TW082105967A patent/TW258663B/zh not_active IP Right Cessation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0389282A2 (en) *	1989-03-23	1990-09-26	BEECHAM - WUELFING GmbH & Co. KG	Xanthinederivatives, process for their preparation and their pharmaceutical use

Also Published As

Publication number	Publication date
WO1994002150A1 (en)	1994-02-03
MX9304435A (es)	1994-04-29
TW258663B (th)	1995-10-01
GB9215633D0 (en)	1992-09-09
ZA935339B (en)	1995-01-18
EP0651642A1 (en)	1995-05-10
CN1114880A (zh)	1996-01-17
JPH07509456A (ja)	1995-10-19
AU4714393A (en)	1994-02-14

Legal Events

Date	Code	Title	Description
1996-01-17	C06	Publication
1996-01-17	PB01	Publication
1999-06-16	C14	Grant of patent or utility model
1999-06-16	GR01	Patent grant
2013-08-21	C17	Cessation of patent right
2013-08-21	CX01	Expiry of patent term	Expiration termination date: 20130722 Granted publication date: 19990616

Publication	Publication Date	Title
CN1043610C (zh)	1999-06-16	新的治疗剂
CN1085527C (zh)	2002-05-29	增效复方抗疟药本芴醇的制备方法
KR0148589B1 (ko)	1998-11-02	항종양 효과의 상승 및 종양의 치료를 위한 조성물 및 키트
CN1622805A (zh)	2005-06-01	包含止泻药和埃坡霉素或埃坡霉素衍生物的组合
EP0269303B1 (en)	1993-08-04	Piperidine derivative for treating pain
CN1108093A (zh)	1995-09-13	抑制血管舒缩症状和护理有关绝经后综合征心理障碍的方法
RU97104483A (ru)	1999-05-20	Соль янтарной кислоты 4-[2-амино-6-(циклопропиламино)-9н-пурин-9-ил]-2- циклопентен-1-метанола в качестве антивирусного агента
CN1156456A (zh)	1997-08-06	作为抗病毒剂的4-[2-氨基-6-(环丙基氨基)-9h-嘌呤-9-基]-2-环戊烯-1-甲醇琥珀酸盐
RU2004131214A (ru)	2005-04-10	Способы лечения когнитивных расстройств
JPS63270626A (ja)	1988-11-08	抗潰瘍剤
US3705946A (en)	1972-12-12	Method of treating hyperuricemia
AU2002334001B2 (en)	2007-07-19	Use of ginkgo biloba extracts for preparing a medicine for treating sarcopenia
HU198388B (en)	1989-10-30	Process for producing pharmaceutical compositions containing amides of carboxylic acids for treating rheumatic and inflammatoric illnesses
CN1107707A (zh)	1995-09-06	抑制体重增加或诱发体重减轻的方法
CN1077790C (zh)	2002-01-16	青光眼治疗剂及眼压降低剂
CN86107991A (zh)	1987-08-05	抗高血压复合物
JP3982889B2 (ja)	2007-09-26	イブプロフェン含有医薬製剤
CN105832724A (zh)	2016-08-10	吲哚醇在制备抗抑郁症药物中的用途
JP4627574B2 (ja)	2011-02-09	消化管運動改善剤
KR20010021796A (ko)	2001-03-15	선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법
JP4078397B2 (ja)	2008-04-23	下痢の予防及び治療剤
CN1078468C (zh)	2002-01-30	叶绿素铜钠盐用于制造抗胃粘膜损伤的组合物的用途
CN1080851A (zh)	1994-01-19	生长激素释放抑制因子的增强剂
EP2146713A2 (fr)	2010-01-27	Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
CN1109331A (zh)	1995-10-04	抑制强迫性神经官能症和消耗性失调的方法